Significance of viral load, core promoter/precore mutations and specific sequences of polymerase gene in HBV-infected patients on 3-year lamivudine treatment

Antiviral Therapy

Volumn 11, Issue 6, 2006, Pages 779-786

  Yuen, Man Fung ^a   Sablon, Erwin ^b   Libbrecht, Evelien ^b   Van De Velde, Hilde ^b   Wong, Danny Ka Ho ^a   Fung, James ^a   Wong, Benjamin Chun Yu ^a   Lai, Ching Lung ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b INNOGENETICS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEROCONVERSION; TREATMENT DURATION; VIRUS CORE; VIRUS GENE; VIRUS LOAD; WILD TYPE; YMDD GENE;

ADOLESCENT; ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DNA, VIRAL; DNA-DIRECTED DNA POLYMERASE; FEMALE; HEPATITIS B CORE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); PROMOTER REGIONS, GENETIC; PROTEIN PRECURSORS; REVERSE TRANSCRIPTASE INHIBITORS; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 33749324215     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339:61-68.
2. Yuen MF, Lai CL. Treatment of chronic hepatitis B. Lancet Infect Dis 2001; 1:232-241.
3. Yuen MF, Sablon E, Hui CK, et al. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001; 34 (4 Pt 1):785-791.
4. Lai CL, Gane E, Liaw YF, Thongsawat S, et al. Maximal early HBV suppression is predictive of optimal virologic and clinical efficacy in nucleoside-treated hepatitis B patients: scientific observations from a large multinational trial (the GLOBE Study). Hepatology 2005; 40 Suppl 1: 232A.
5. Ciancio A, Smedile A, Rizzetto M, et al. Identification of HBV DNA sequences that are predictive of response to lamivudine therapy. Hepatology 2004; 39:64-73.
6. Yuen MF, Wong DK, Sablon E, et al. Hepatitis B virus genotypes B and C do not affect the antiviral response to lamivudine. Antivir Ther 2003; 8:531-534.
7. Westland C, Delaney W 4th, Yang H, et al. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. Gastroenterology 2003; 125:107-116.
8. Asahina Y, Izumi N, Uchihara M, et al. Core promoter/precore mutations are associated with lamivudine-induced HBeAg loss in chronic hepatitis B with genotype C. J Hepatol 2003; 39:1063-1069.
9. Lin CL, Liao LY, Wang CS, et al. Evolution of hepatitis B virus precore/basal core promoter gene in HBeAg-positive chronic hepatitis B patients receiving lamivudine therapy. Liver Int 2004; 24:9-15.
10. Suzuki F, Suzuki Y, Tsubota A, et al. Mutations of polymerase, precore and core promoter gene in hepatitis B virus during 5-year lamivudine therapy. J Hepatol 2002; 37:824-830.
11. Cho SW, Hahm KB, Kim JH. Reversion from precore/core promoter mutants to wild type hepatitis B virus during the course of lamivudine therapy. Hepatology 2000; 32:1163-1169.
12. Yuen MF, Sablon E, Yuan HJ, et al. Relationship between the development of precore and core promoter mutations and hepatitis B e antigen seroconversion in patients with chronic hepatitis B virus. J Infect Dis 2002; 186:1335-1338.
13. Stuyver L, Van Geyt C, De Gendt S, et al. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy. J Clin Microbiol 2000; 38:702-707.
14. Yuen MF, Wong DK, Sum SS, et al. Effect of lamivudine therapy on the serum covalently closed-circular (ccc) DNA of chronic hepatitis B infection. Am J Gastroenterol 2005; 100:1099-1103.
15. Yuen MF, Yuan HJ, Sablon E, et al. Long-term follow-up study of Chinese patients with YMDD mutations: significance of hepatitis B virus genotypes and characteristics of biochemical flares. J Clin Microbiol 2004; 42:3932-3936.
16. Akuta N, Suzuki F, Kobayashi M, et al. The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment. J Hepatol 2003; 38:315-321.
17. Kao JH, Liu CJ, Chen DS. Hepatitis B viral genotypes and lamivudine resistance. J Hepatol 2002; 36:303-304.
18. Lurie Y, Manns MP, Gish RG, et al. The efficacy of entecavir is similar regardless of disease-related baseline subgroups in treatment of nucleoside-naïve, HBeAg(+) and HBeAg(-) patients with chronic hepatitis B. J Hepatol 2005; 42(Suppl 2):184.
19. Shin JW, Chung YH, Choi MH, et al. Precore stop codon mutation of hepatitis B virus is associated with low breakthrough rate following long-term lamivudine therapy. J Gastroenterol Hepatol 2005; 20:844-849.